A single human genome contains roughly 3 billion base pairs. Whole genome sequencing (WGS), used to ‘read’ the DNA, generates hundreds of gigabytes per patient. As such, genomic analysis faces several challenges. Not only in the amount of data, which requires storage, infrastructure and processing power, but also in the interpretation complexity.
Quantum machine learning (QML) combines quantum computing principles with learning algorithms and therefore brings unparalleled computational power that can fundamentally transform how genomic data is analysed.
Case: Genomic data analysis with quantum machine learning
Genomic analysis is becoming increasingly important in healthcare to identify genetic markers, diagnose rare diseases, develop individualised therapies, predict disease patterns or conditions, and support cancer research.
Genomic data isn’t just large; it’s high-dimensional. To understand the cause of a specific disease, the interactions between 10 different genes need to be mapped. This involves exponential combinations. Classical algorithms use linear or sequential processing and struggle to classify complex genetic patterns.
Quantum computers use superposition and entanglement, allowing them to process these combinations simultaneously rather than one by one. They can compare a patient’s DNA to a reference in a fraction of the time needed by classical systems. As such, quantum machine learning can be more accurate and can recognise subtle patterns classical algorithms fail to see. Quantum machine learning drives genomic analysis forward by:
- Performing more precise diagnostics
- Enhancing preventive healthcare through early risk detection
- Developing personalised medicine strategies tailored to an individual’s genetic profile
Business value
- Personalised Healthcare: QML improves the detection of gene interactions and rare variant combinations that influence treatment response, enabling tailored treatment plans.
- Faster Diagnostics: Quantum algorithms process high-dimensional sequence alignments exponentially faster, reducing the time to diagnose genetic disorders from years to hours.
- Cost Reduction: QML optimises feature selection and compresses complex search spaces, reducing computational overhead for certain tasks.
- Population Health: Quantum-enhanced modelling enables the identification of emerging disease trends and genetic risk factors across entire populations in real time.
Technology readiness
Quantum machine learning for genomics is still in the research and exploratory pilot phase. Most published work today involves small proof-of-concept studies, simulated quantum environments, hybrid quantum–classical models, and synthetic or downscaled genomic datasets.
Classical machine learning remains industry standard today, amongst other reasons, because it is reliable, well-integrated into clinical workflows and has established regulatory pathways. QML is advancing rapidly but is in the Noisy Intermediate-Scale Quantum (NISQ) era: limited in qubit count, sensitive to noise, and error prone.
Startups are increasingly partnering with regional authorities and academic institutions to create innovation ‘clusters’ to build manufacturing and computing facilities specifically for quantum applications. Major pharmaceutical players are investing now to develop the capabilities to use quantum methods for complex problems like mRNA folding as hardware matures.
Leading players and experiments
GE HealthCare is integrating multimodal genomic and pathology data into deep learning models.
IBM, through its Discovery Accelerator partnership with the Cleveland Clinic, uses its quantum hardware to optimise human genome sequencing and identify candidate drugs for repurposing in neurodegenerative diseases.
Google’s Quantum AI team focuses on algorithms for today’s pre-error-corrected processors to simulate molecular systems and gene expression. Much of their work remains at the proof-of-concept and academic stage.
Menten AI developed what is regarded as the first peptide designed on a quantum computer and is using a hybrid platform to create cyclic peptides for conditions like COVID-19 and cancer. Within the same area of expertise, ProteinQure specialises in high-accuracy simulations for protein-based drug discovery.
The National Institutes of Health (NIH) fund the development of quantum-optimised treatment plans and personalised medicine strategies across academic and private sectors.
Discover more use cases here.
